VK0214
VK0214-102
Phase 1 small_molecule completed
Quick answer
VK0214 for Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) is a Phase 1 program (small_molecule) at Viking Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Viking Therapeutics
- Indication
- Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed